Marksans Pharma Financial Statements

Switch to
Tabular Data
Graph
Switch to
Consolidated
Standalone
Y/e 31 Mar Mar-2020 Mar-2018 Mar-2017 Mar-2016
Growth matrix (%)        
Revenue growth 24.30 19 (14) 12.10
Op profit growth 122 93.30 (67) (26)
EBIT growth 176 177 (81) (32)
Net profit growth 255 273 (89) (28)
Profitability ratios (%)        
OPM 17 9.48 5.83 15.30
EBIT margin 14.60 6.58 2.83 13.10
Net profit margin 10.30 3.61 1.15 8.79
RoCE 25.80 10.30 3.91 22.70
RoNW 5.29 1.82 0.50 4.71
RoA 4.55 1.42 0.40 3.80
Per share ratios ()        
EPS 2.95 0.87 -- 1.99
Dividend per share 0.10 0.05 0.05 0.41
Cash EPS 2.21 0.15 (0.50) 1.23
Book value per share 15.50 11.50 10.60 11.10
Valuation ratios        
P/E 4.71 36.40 -- 23.20
P/CEPS 6.30 212 (91) 37.50
P/B 0.89 2.75 4.45 4.28
EV/EBIDTA 2.57 15.80 38.90 13.40
Payout (%)        
Dividend payout -- 7.49 193 22.90
Tax payout (23) (28) (24) (23)
Liquidity ratios        
Debtor days 67.60 84.90 111 81.90
Inventory days 74 81.60 85.10 60.90
Creditor days (35) (53) (71) (54)
Leverage ratios        
Interest coverage (19) (5.90) (3.20) (12)
Net debt / equity (0.10) 0.17 0.20 0.12
Net debt / op. profit (0.40) 0.90 1.89 0.39
Cost breakup ()        
Material costs (48) (57) (60) (57)
Employee costs (15) (16) (20) (14)
Other costs (20) (17) (15) (14)
Switch to
Tabular Data
Graph
Switch to
Consolidated
Standalone
Y/e 31 Mar( In .Cr) Mar-2020 Mar-2018 Mar-2017 Mar-2016
Revenue 1,134 913 767 893
yoy growth (%) 24.30 19 (14) 12.10
Raw materials (545) (523) (459) (510)
As % of sales 48 57.30 59.80 57.10
Employee costs (168) (148) (150) (122)
As % of sales 14.80 16.20 19.50 13.70
Other costs (229) (155) (114) (125)
As % of sales 20.20 17 14.90 14
Operating profit 192 86.50 44.70 136
OPM 17 9.48 5.83 15.30
Depreciation (27) (27) (30) (28)
Interest expense (8.70) (10) (6.80) (10)
Other income 0.33 0.36 7.02 8.87
Profit before tax 157 49.80 14.90 107
Taxes (36) (14) (3.60) (24)
Tax rate (23) (28) (24) (23)
Minorities and other (3.70) (2.90) (2.50) (4.20)
Adj. profit 117 32.90 8.84 78.50
Exceptional items -- -- -- --
Net profit 117 32.90 8.84 78.50
yoy growth (%) 255 273 (89) (28)
NPM 10.30 3.61 1.15 8.79
Switch to
Tabular Data
Graph
Y/e 31 Mar ( In .Cr) Mar-2020 Mar-2018 Mar-2017 Mar-2016
Profit before tax 157 49.80 14.90 107
Depreciation (27) (27) (30) (28)
Tax paid (36) (14) (3.60) (24)
Working capital 584 474 196 105
Other operating items -- -- -- --
Operating cashflow 678 483 177 159
Capital expenditure 225 245 200 168
Free cash flow 903 728 377 327
Equity raised 353 171 409 431
Investments -- -- -- --
Debt financing/disposal (116) (61) (53) 139
Dividends paid -- 2.05 2.05 16.80
Other items -- -- -- --
Net in cash 1,140 840 735 914
Switch to
Tabular Data
Graph
Switch to
Consolidated
Standalone
Y/e 31 Mar ( In .Cr) Mar-2020 Mar-2019 Mar-2018 Mar-2017
Equity capital 40.90 40.90 40.90 40.90
Preference capital -- -- -- --
Reserves 595 502 430 393
Net worth 636 542 471 433
Minority interest
Debt 18.90 100 118 110
Deferred tax liabilities (net) 13.40 8.56 7.57 6.75
Total liabilities 681 661 606 556
Fixed assets 303 270 279 267
Intangible assets
Investments -- -- -- --
Deferred tax asset (net) 3.20 2.78 3.01 2.64
Net working capital 282 355 284 261
Inventories 242 293 218 190
Inventory Days 77.80 -- 87.20 90.40
Sundry debtors 243 177 177 248
Debtor days 78.30 -- 70.70 118
Other current assets 14.60 29.40 16.50 21.70
Sundry creditors (105) (106) (78) (162)
Creditor days 33.60 -- 31.10 77
Other current liabilities (114) (38) (50) (37)
Cash 93.70 33.50 39.90 25.20
Total assets 681 661 606 556
Switch to
Consolidated
Standalone


Particulars ( Rupees In Crores.) Mar-2020 Mar-2019 Mar-2018 Mar-2017 Mar-2016
Gross Sales 1,134 1,000 913 767 893
Excise Duty -- -- -- -- --
Net Sales 1,134 1,000 913 767 893
Other Operating Income -- -- -- -- --
Other Income 0.33 4.62 8.47 7.02 8.87
Total Income 1,135 1,005 921 774 902
Total Expenditure ** 942 868 834 722 757
PBIDT 193 137 86.90 51.80 145
Interest 8.75 9.66 10.20 6.78 10.20
PBDT 184 127 76.60 45 135
Depreciation 26.70 22.80 26.80 30.10 28.10
Minority Interest Before NP -- -- -- -- --
Tax 32 22.90 13.40 1.73 27.50
Deferred Tax 4.47 1.01 0.60 1.83 (3.40)
Reported Profit After Tax 121 80.40 35.80 11.30 82.70
Minority Interest After NP -- -- -- -- 4.23
Net Profit after Minority Interest 121 80.40 35.80 11.30 78.50
Extra-ordinary Items -- -- -- -- --
Adjusted Profit After Extra-ordinary item 121 80.40 35.80 11.30 78.50
EPS (Unit Curr.) 2.86 1.87 0.80 0.22 1.92
Book Value (Unit Curr.) -- -- -- -- --
Dividend (%) 10 5 5 5 12
Equity 40.90 40.90 40.90 40.90 40.90
Public Shareholding (Number) -- -- -- -- --
Public Shareholding (%) -- -- -- -- --
Pledged/Encumbered - No. of Shares -- -- -- -- --
Pledged/Encumbered - % in Total Promoters Holding -- -- -- -- --
Pledged/Encumbered - % in Total Equity -- -- -- -- --
Non Encumbered - No. of Shares -- -- -- -- --
Non Encumbered - % in Total Promoters Holding -- -- -- -- --
Non Encumbered - % in Total Equity -- -- -- -- --
PBIDTM(%) 17 13.70 9.52 6.75 16.20
PBDTM(%) 16.20 12.70 8.40 5.86 15.10
PATM(%) 10.60 8.04 3.92 1.48 9.26